
Novel Agents in the
Treatment of Lung Cancer
New Approaches to First-Line Therapies
A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.
Table of Contents
Challenging Existing Paradigms for Optimal First-line Treatment of Advanced NSCLC
Targeted Antibody Therapy with Chemotherapy in First-Line NSCLC
Anti-EGFR Antibody (Cetuximab) in Combination with Chemotherapy in First-line Treatment of NSCLC
Using Markers to Select Patients for Anti-EGFR Antibody Therapy
Using EGFR Mutations to Select Patients for First-line EGFR TKI Therapy (Erlotinib, Gefitinib)
A Monoclonal Antibody Against the IGF-IR for the Treatment of NSCLC
Role of Maintenance Therapy
Defining the Optimal Duration of Chemotherapy in Advanced NSCLC
Pemetrexed, Docetaxel, and Erlotinib in Maintenance Therapy
New Ventures in Up-front Supportive Care
Integration of Early Palliative Care in the Treatment of Metastatic NSCLC